Physician profile
Theresa Nguyen
NPI 1356994347
$8,789.29
in general payments reported to CMS, 2019-2025
11 companies · $7,331 in 2025
The $7,331 reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $339 · 2022: $485 · 2023: $511 · 2024: $124 · 2025: $7,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,203 · Food and Beverage: $763.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,203.00 |
| Food and Beverage | $763.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $7,203.00 | 2025 | |
| Servier Pharmaceuticals LLC | $357.49 | 2022-2025 | |
| Incyte Corporation | $223.69 | 2021-2022 | |
| Abbvie INC. | $218.00 | 2021-2023 | |
| Seagen INC. | $146.05 | 2023 | Adcetris |
| Alexion Pharmaceuticals, INC. | $145.08 | 2021-2023 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $124.99 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $123.88 | 2024 | Reblozyl |
| Beigene USA, INC. | $114.94 | 2021 | |
| Glaxosmithkline, LLC. | $112.97 | 2023 | Ojjaara |
| Astrazeneca Pharmaceuticals Lp | $19.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theresa Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.